ipmn.org
Our Supporters - Innocence Project of Minnesota
http://ipmn.org/who-we-are/supporters
Innocence Project of Minnesota. Help Free the Innocent. What Cases We Review. Additional Stories of Innocence. New Corporate CLE Offering. Review of 14,000 DNA Cases. Books about Wrongful Conviction. Movies about Wrongful Conviction. 2016 Benefit for Innocence. 4th Annual Hotrod Breakout Benefit. 2016 Wrongful Convictions Day. What Cases We Review. Additional Stories of Innocence. New Corporate CLE Offering. Review of 14,000 DNA Cases. Books about Wrongful Conviction. Movies about Wrongful Conviction.
andaadvisors.com
Federal Circuit Discounts Commercial Success Evidence Even Though Alleged Invention Helped Secure Regulatory Approval - Carlson Caspers's ANDA Advisors BlogCarlson Caspers's ANDA Advisors Blog
http://andaadvisors.com/federal-circuit-discounts-commercial-success-evidence-even-though-alleged-invention-helped-secure-regulatory-approval
May 13, 2015. Federal Circuit Discounts Commercial Success Evidence Even Though Alleged Invention Helped Secure Regulatory Approval. Last Thursday, in its decision in AstraZeneca LP v Breath Ltd. 13-cv-3372 (S.D.N.Y April 8, 2012) ( [T]he Court is hesitant to equate regulatory success to commercial success . . . ). Carlson Caspers led the invalidity challenge during the underlying trial for this matter. Our Pharmaceutical Litigation Team. Jennell C. Bilek. Wendy M. Bratten. Jonathan D. Carpenter.
andaadvisors.com
Court Permits FDA to Carve Out Indications, Despite Brand Name’s Orphan Drug Status - Carlson Caspers's ANDA Advisors BlogCarlson Caspers's ANDA Advisors Blog
http://andaadvisors.com/court-permits-fda-to-carve-out-indications-despite-brand-names-orphan-drug-status
May 7, 2015. Court Permits FDA to Carve Out Indications, Despite Brand Name’s Orphan Drug Status. A United States District Court has decided generic versions of aripiprazole (Abilify. May proceed to market despite the brand name drug’s orphan drug status. On April 28, 2015, the FDA approved four generic versions of aripiprazole (Abilify. Case No. GJH-15-852 (D. Md. filed Apr. 29, 2015). 21 USC. 360cc(a). Our Pharmaceutical Litigation Team. Jennell C. Bilek. Wendy M. Bratten. Jonathan D. Carpenter. Nathan...
andaadvisors.com
PIV Certifications Do Not PrecludeCarlson Caspers's ANDA Advisors Blog
http://andaadvisors.com/piv-certifications-do-not-preclude-ipr-challenges
April 16, 2015. PIV Certifications Do Not Preclude IPR Challenges. PIV certifications do not preclude ANDA filers from seeking inter partes. Review of Orange Book patents, according to the court in Senju Pharmaceutical Co. v. Metrics, Inc. 14-CV-3962 (D. N.J. Mar. 31, 2015). Plaintiffs Senju and Bausch and Lomb own three patents covering formulations of bromfenac, the active ingredient in Prolensa. Six days after the complaint was filed, Metrics filed IPR petitions with the PTAB for the asserted patents.
andaadvisors.com
About Us - Carlson Caspers's ANDA Advisors BlogCarlson Caspers's ANDA Advisors Blog
http://andaadvisors.com/about-us
And Best Lawyers in America. Carlson Caspers offers a wide variety of services related to the management and enforcement of intellectual property. Our services include representing individuals and companies in all aspects of intellectual property and related litigation; preparing infringement, validity, landscape, freedom-to-operate, and due diligence opinions; and preparing intellectual property licensing, assignment, and other agreements. Our Pharmaceutical Litigation Team. Jennell C. Bilek.
andaadvisors.com
Disclaimer - Carlson Caspers's ANDA Advisors BlogCarlson Caspers's ANDA Advisors Blog
http://andaadvisors.com/disclaimer
This website is provided for informational purposes only and does not represent legal advice on any subject matter. The contents of this website should not be relied upon or used as a substitute for consultation with professional advisors. You should contact your attorney to obtain advice with respect to any particular issue or problem. Our Pharmaceutical Litigation Team. Jennell C. Bilek. Wendy M. Bratten. Jonathan D. Carpenter. Matthew J. Goggin. Peter M. Kohlhepp. Samuel T. Lockner. Gary J. Speier.
iprworkshop.com
Workshop on critical patenting Issues on Pharma & biosimilar
http://www.iprworkshop.com/faculty.html
Global IP Convention 2016. ITAG Business Solutiond Ltd. Schwegman Lundberg and Woessner. Gary J. Speier. Monique M. Perdok. Is a litigator who advises and represents clients in intellectual property matters, with particular emphasis in the life sciences. Having obtained a Doctor of Pharmacy degree and practiced as a pharmacist before attending law school. Sarah M. Stensland. Dr D R. Agarwal.
andaadvisors.com
Sitemap - Carlson Caspers's ANDA Advisors BlogCarlson Caspers's ANDA Advisors Blog
http://andaadvisors.com/sitemap
Delaware Recognizes Declaratory Judgment Action Concerning Biosimilar Applicant’s Failure to Give Notice of Commercial Marketing. No Personal Jurisdiction over Foreign Patentee in Benicar Saga. ANDA Statements Fatal to DOE Defense. Biosimilar Applicants Cannot Avoid 180-Day Notice Requirement. Submission of New Evidence After Institution of an IPR is Perfectly Permissible. Supreme Court Upholds Broadest Reasonable Claim Construction Standard; Confirms Decision to Institute IPRs Remains Unappealable.